Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

PRINCETON, N.J.— November 3, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William F. Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. A webcast of the fireside chat will be available beginning … Continued

Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services

Pinnacle 21 Enterprise software expedites regulatory review of all study submission data Princeton, N.J., October 28, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has awarded a five-year contract with Pinnacle 21 for ongoing software and related services support for the agency’s DataFit … Continued

Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, NJ – October 25, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in … Continued

Certara Appoints Patrick F. Smith to President of Integrated Drug Development

Princeton, N.J., October 12, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery.  Dr. Smith will lead the Company’s global drug development services team, which creates value for clients across the … Continued

Certara Appoints Drayton T. Virkler as Chief Commercial Officer

Experienced commercial leader brings 20 years of experience in pharma Princeton, N.J., October 5, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company’s global commercial strategy and … Continued

Certara Senior Scientific Leader Receives 2021 Leadership Award by International Society of Pharmacometrics

Recognizes those who have advanced the field of pharmacometrics and its future direction PRINCETON, NJ.— October 4, 2021 – Certara, Inc., the global leader in biosimulation, today announced that Piet van der Graaf, Pharm.D., Ph.D,. is the recipient of the 2021 Leadership Award by the International Society of Pharmacometrics (ISoP) for his outstanding sustained leadership, … Continued

Certara Completes Acquisition of Pinnacle 21

Complementary technologies accelerate and help assure success in the drug development process Princeton, N.J., October 4, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness.  … Continued

Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process

Cloud-based and validated regulatory software automates and advances quality of patient narratives Princeton, N.J., September 30, 2021 – Certara, a global leader in biosimulation, today announced the launch of Synchrogenix™ Writer, a new regulatory SaaS product that expedites the authoring and review of patient narratives. Patient narratives describe adverse events or adverse drug reactions and … Continued

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities PRINCETON, N.J.— September 22, 2021. Certara, a global leader in biosimulation, today announced that it is expanding its Integrated Drug Development (IDD) division with a new clinical science group, headed up by Philippa Marshall, M.D., Vice President of Clinical Science.  The Company also appointed David Mitchell, … Continued

2 of 29
Back to top
Powered by Translations.com GlobalLink OneLink Software